Advertisement

Systematic review of mental health comorbidities in psoriatic arthritis

  • Sizheng Steven Zhao
  • Natasha Miller
  • Nicholas Harrison
  • Stephen J. Duffield
  • Mrinalini Dey
  • Nicola J. GoodsonEmail author
Open Access
Original Article

Abstract

Objective

In this systematic review and meta-analysis of psoriatic arthritis (PsA) studies, we pooled data from existing literature to (1) estimate the prevalence of mental health disorders in PsA patients and (2) compare disease activity in PsA patients with and without these comorbidities.

Method

We searched PubMED, Web of Science, Scopus, PsycINFO and the Cochrane Library using a predefined protocol in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Where possible, meta-analysis was performed using random effects model. Prevalence estimates were pooled according to the severity of mental health disorders.

Results

A total of 24 studies, amounting to 31,227 PsA patients, were included for review. Anxiety and depression were the only consistently reported mental health disorders, defined using a range of screening criteria/thresholds. Anxiety prevalence ranged from 4 to 61% with a pooled estimate of 33% (95%CI 17 to 53%) having at least mild anxiety and 21% (95%CI 14 to 29%) at least moderate. Depression prevalence ranged from 5 to 51%, with 20% (95%CI 8 to 35%) having at least mild and 14% (95%CI 8 to 21%) at least moderate. Only two studies compared disease activity according to the presence of mental health comorbidities; both reported higher disease activity and pain among those with comorbid anxiety and depression.

Conclusions

Anxiety and depression are highly prevalent among PsA patients. Studies of other mental health disorders were scarce. More studies are needed on the impact of these comorbidities on disease activity and long-term outcomes.

Key Points

One in three patients with psoriatic arthritis has at least mild anxiety, while 1 in 5 reported at least mild depression.

PsA patients with anxiety and/or depression reported greater disease activity.

More research is needed on other mental health comorbidities, particularly sleep, suicide/self-harm and substance misuse.

Keywords

Anxiety Comorbidity Depression Mental health Meta-analysis Prevalence Psoriatic arthritis Sleep Systematic review 

Background

Psoriatic arthritis (PsA) affects 0.3 to 1% of the general population and up to 30% of those with psoriasis [1]. The articular manifestations can be debilitating, afflicting varying number and distribution of peripheral joints as well as the axial skeleton. In addition, multiple domains of health can be affected by skin involvement, numerous other disease features (e.g. enthesitis, dactylitis, nail disease, uveitis) and additional, co-existing morbidities [2]. Mental health disorders are an important and highly prevalent group of comorbidities in patients with psoriasis [3], but their prevalence and impact in PsA have not been systematically reviewed. Prevalence of these comorbidities may differ between the two disease groups since PsA cohorts tend to be older and have a longer duration of skin involvement—the majority of PsA patients have had skin involvement for ~ 10 years [1]. Psoriasis patients who develop arthritis have higher levels of fatigue and psychological distress [4]. In patients with PsA, joint involvement appears to affect the quality of life to a greater extent than skin [5].

Improving the understanding of mental health comorbidities in PsA has significant clinical implications. Studies have shown that patients with depression have increased the perception of pain [6]. Poor mental health is also a key predictor for secondary fibromyalgia [7] which, in turn, is associated with worse patient-reported outcomes [8]. These comorbidities present challenges when trying to treat PsA to target. Composite treatment targets, such as DAS28 [9] or minimal disease activity [10], include components (tender joint count, pain and patient global visual analogue scales) that may be influenced by comorbid mental health conditions. Treatment escalation driven by non-inflammatory symptoms may lead to toxicity. This is particularly important in PsA management since tight control was associated with more adverse events than standard care, was not superior for radiological damage, and only provided modest improvements to the quality of life [11].

The aims of this systematic review were to (1) describe the prevalence of comorbid mental health disorders in PsA and (2) compare disease activity scores in PsA patients with and without these  comorbidities.

Methods

We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12]. The protocol was registered in advance (PROSPERO: CRD42017079841). We searched PubMED, Web of Science, Scopus, PsycINFO and the Cochrane Library through February 2019. Details of the search strategy are shown in Supplementary Materials.

Studies recruiting adult patients were included if they reported the prevalence of a comorbid mental health disorder or assessed the effect of a comorbid mental health disorder on disease activity. Studies were excluded if they used non-representative sampling (highly selective recruitment criteria, such as studies that only recruited women), had a sample size of less than 30 (to avoid unreliable prevalence estimates) or used the same cohort as an existing study. Only full-length articles were considered; reviews, comments and editorials were excluded.

Two reviewers independently assessed the eligibility of articles for inclusion and extracted data from suitable studies. Disagreements were resolved through discussion moderated by a third reviewer. Information from included studies was extracted into predefined tabulated summaries containing: study design, sample size, criteria used to diagnose the psoriatic arthritis and mental health disorders, age gender and prevalence of comorbid mental health disorders. Where available, disease activity scores for patients with and without comorbid mental health disorders were also extracted.

Commonly used thresholds for each screening tool were applied to categorise severity of depression. For the Hospital Anxiety and Depression Scale (HADS) anxiety and depression subscales, a scale of ≤ 7 was interpreted as no anxiety/depression, 8 to 10 as mild, 11 to 14 moderate, and ≥ 15 severe [13]. The Patient Health Questionnaire (PHQ-9) thresholds were ≤ 5 no depression, 6 to 10 mild, 11 to 14 moderate and ≥ 15 severe [14]. Hamilton Depression Scale (HAM-D) is as follows: ≤ 7 no depression, 8 to 13 mild, 14 to 18 moderate and ≥ 19 severe depression [15]. For the Generalised Anxiety Disorder questionnaire (GAD-7), a scale of ≤ 5 was taken to indicate no anxiety, 6 to 9 mild, 10 to 14 moderate and ≥ 15 severe [16]. Studies that used similar thresholds were grouped together. We also included studies using components from the quality of life questionnaires to screen for anxiety or depression. The 5-domain EuroQol questionnaire (EQ-5D) has a single question with the options: I am not anxious or depressed; I am moderately anxious or depressed; I am extremely anxious or depressed. Although not a validated method, single-item screening questionnaires have good sensitivity and specificity [17]. The Short-Form Health Survey (SF-36) mental health subscale (MH) and mental component summary (MCS) score also perform well as a screening method [18]. The PsA quality of life questionnaire includes one item “I feel there is no enjoyment in my life” [19]. If a study reported depression prevalence using two different thresholds, it could contribute to more than one pooled estimate.

Quality assessment of included studies was performed using the Newcastle-Ottawa Scale (NOS), adapted for cross-sectional studies [20]. Articles were assigned up to six stars depending on the rigour of the methodological approach used (see Supplementary Materials for details).

Statistical analysis

Prevalence was presented as percentages (95% confidence interval, I2 statistic). Proportional meta-analysis was performed using double arcsine transformation [21], with results presented using random effects models (DerSimonian-Laird). Heterogeneity of meta-analysis estimates was presented using the I2 statistic. Funnel and Doi plots were used to assess the risk of publication bias [21]. Where available, differences in markers of disease activity and functional impairment were compared between groups with and without depression. Analyses were performed using MetaXL Version 5.3 (Sunrise Beach, Australia; www.epigear.com).

Results

The searched returned a total of 1216 unique publications. After screening and full-text assessment, 27 studies met eligibility criteria. Among these, three were excluded as they used the same cohort as other included studies [22, 23, 24]. A flowchart of the selection process is shown in Supplementary Fig. 1.

Details extracted from the 24 included studies are shown in Table 1. Collectively they assessed the prevalence of comorbid mental health disorders in 31,227 psoriatic arthritis patients. Individual study sample sizes varied from 41 to 4795. Seventeen studies were cross-sectional in design and 7 were longitudinal (including 2 trials). PsA was defined using a number of approaches: the CASPAR criteria was used in 8 studies (only part of the population fulfilled the criteria in 2), 8 relied on physician/rheumatologist diagnosis only, 5 used ICD (International Classification of Diseases) codes, 2 used patients’ self-report and 1 used the Moll and Wright criteria.
Table 1

Summary of study characteristics, prevalence of depression and quality of studies included in this meta-analysis

Study

Study design

PsA definition

Sample size

Age, mean (SD)

Females, %

Mental health comorbidity

Prevalence, %

Criteria or definition used

Cauli (2011) [25]

CS

CASPAR

319

52 (13)

42

Anxiety

13.4

HADS ≥ 11

Depression

11.6

McDonough (2014) [26]

CS

CASPAR

306

54 (13)

39

Anxiety (HADS-A ≥ 8)

Anxiety (HADS-A ≥ 11)

36.6

15.0

HADS

Depression (HADS-D ≥ 8)

Depression (HADS-D ≥ 11)

22.3

9.2

Anxiety and depression

(HADS-A and -D ≥ 8)

17.7

Anxiety and depression

(HADS-A and -D ≥ 11)

3.9

Gniadecki (2012) [27]

RCT

Diagnosed by rheumatologist, trained assessor or dermatologist

752

47

37

Anxiety (HADS-A ≥ 8)

Anxiety (HADS-A ≥ 11)

54

30

HADS

Depression (HADS-D ≥ 8)

Depression (HADS-D ≥ 11)

37

16

Meesters (2014) [28]

CS

ICD-10 codes

1185

58 (14)

58

Anxiety (HADS-A ≥ 8)

Anxiety (HADS-A ≥ 11)

Anxiety (HADS-A ≥ 15)

30.5

13.5

4.0

HADS

Depression (HADS-D ≥ 8)

Depression (HADS-D ≥ 11)

Depression (HADS-D ≥ 15)

14.8

4.5

0.9

Anxiety and depression

(HADS-A and -D ≥ 8)

11.2

Howell (2018) [29]

CS

Self-report of physician diagnosis

179

45 (10)

77

Anxiety (HADS-A ≥ 8)

Anxiety (HADS-A ≥ 11)

60.8

40.9

HADS

Depression (HADS-D ≥ 8)

Depression (HADS-D ≥ 11)

51.2

28.2

Freire (2011) [30]

CS

Rheumatologist diagnosis

495

50 (13)

43

Anxiety

29.7

HADS ≥ 11 or receiving pharmacological treatment

Depression

17.6

Anxiety and depression

14.3

Lamb (2017) [31]

CS

Rheumatologist diagnosis

109

NS

NS

Anxiety (GAD-7 ≥ 10)

Anxiety (GAD-7 ≥ 15)

13.1

8.1

GAD-7

Depression (PHQ-9 ≥ 5)

Depression (PHQ-9 ≥ 20)

9.9

4.1

PHQ-9

Anxiety or depression

14.8

GAD-7/PHQ-9

Anxiety and depression

8.1

Kotsis (2012) [32]

CS

CASPAR

83

49 (12)

47

Depression

21.7

PHQ-9 ≥ 10 (at least moderate)

Papp (2014) [33]

RCT

Physician diagnosis

523

47 (13)

33

Depression

32.4

HAM-D ≥ 7 (at least mild)

Torre-Alonso (2014) [34]

L

Moll & Wright

197

49 12

42

Anxiety or depression

50

EQ-5D

Michelsen (2017) [35]

L

Rheumatologist diagnosis

728

48 (13)

51

Anxiety or depression

44.8

EQ-5D-3L

15.9

SF-36 MH ≤ 56

25.7

SF-36 MCS ≤ 38

Walsh (2014) [36]

CS

Rheumatologist diagnosis, 93% fulfilled CASPAR

107

NS

44

“Depressed mood”

13.1

PsAQoL Q4 “I feel there is no enjoyment in my life”

Davis (2011) [37]

CS

ICD-9 code

4795

52 (12)

49

Anxiety

3.9

ICD-9 codes

Depression

6.1

Major depressive disorder

3.5

> 1 sleep comorbidity

7.6

Kaine (2019) [38]

L

ICD-9 code

14,898

53 (12)

55

Anxiety

9.2

ICD-9 codes

Depression

13.3

Ballegaad (2017) [39]

L

Physician diagnosis

1750

48 (12)

53

Anxiety or depression

5.4

ICD-10 codes

Altobelli (2007) [40]

CS

Self-reported

508

NS

NS

Depression

30

Self-reported

Sinnathurai (2018) [41]

CS

Physician diagnosis

490

50 (12)

59

Depression

35.9

Self-reported

Patel (2018) [42]

CS

Rheumatologist diagnosis

164

53

39

Depression

7.1

Self-report of receiving antidepressant

Husted (2013) [43]

CS

Physician diagnosis, 98% fulfilled CASPAR

631

50 (13)

41

Anxiety or depression

20.6

Patient-reported and from medical chart review

Khraishi (2014) [44]

CS

CASPAR

196

49 (10)

50

Anxiety or depression

13.8

Patient-reported and from medical chart review

Löfvendahl (2018) [45]

CS

ICD-10 code

2657

55 (16)

56

Mental and behavioural disorders

22.8

ICD-10 codes

Psychiatric disease including schizophrenia and mood disorders

11.3

ICD-10 codes

Wu (2016) [46]

L

ICD-9 code and on biologics

980

45 (13)

31

Depression or insomnia or on antidepressants

35.6

ICD-9 codes

Wong (2017) [47]

CS

CASPAR

113

57 (12)

45

Poor sleep quality

84.1

Pittsburgh Sleep Quality Index ≥ 6

Gezer (2017) [48]

CS

CASPAR

41

41 (13)

61

Poor sleep quality

85.4

Pittsburgh Sleep Quality Index ≥ 6

According to the NOS, the quality of these studies was generally low (range 0 to 4 out of 6 possible stars). Justification of sample size and comparison of patients in/excluded from analyses were particularly lacking (Supplementary Table 1).

The most commonly studied mental health comorbidities were anxiety and depression. Ten studies used validated questionnaires to define anxiety and/or depression (6 HADS with various thresholds, 2 PHQ-9, 1 GAD-7, 1 HAM-D), 5 used components from other questionnaires (2 EQ-5D, 2 SF-36, 1 PsA-QoL), 6 used ICD codes and 5 self-report. Some studies used more than one method, but none used diagnostic criteria. Two studies reported poor sleep as screened using the Pittsburgh Sleep Quality Index (PSQI) [47, 48]; their pooled prevalence was 84% (95%CI 78 to 90%, I2 = 0%).

Prevalence of anxiety

The prevalence of anxiety ranged from 4 to 61%, depending on the HADS thresholds used. Figure 1a shows the prevalence of at least mild anxiety (HADS-A ≥ 8) as 33% (95%CI 17 to 53%, I2 = 99%) [26, 27, 28, 29]. Figure 1b shows the pooled prevalence for at least moderate anxiety (HADS-A ≥ 11 and GAD-7 ≥ 10) as 21% (95%CI 14 to 29%, I2 = 96%) [25, 26, 27, 28, 29, 30, 31]; excluding the single study using GAD-7 [31] did not improve heterogeneity (data not shown). The prevalence of anxiety using ICD-9 codes was 6% (95%CI 2 to 12%, I2 = 99%) [37, 38]. There was major asymmetry in the funnel and Doi plots for both mild and moderate anxiety prevalence estimates (Supplementary Fig. 2).
Fig. 1

Forest plots showing the pooled prevalence of anxiety in studies of PsA. The top panel (a) shows prevalence estimates for at least mild anxiety, and bottom panel (b) at least moderate

Prevalence of depression

The prevalence of depression ranged from 5 to 51%, depending on the thresholds used. The prevalence of at least mild depression (HADS-D ≥ 8, PHQ-9 ≥ 5, HAM-D ≥ 7) was 20% (95%CI 8 to 35%, I2 = 99%; Fig. 2a) [26, 27, 28, 29, 31, 33]; keeping only studies using HADS-D did not improve heterogeneity (data not shown). The pooled prevalence of at least moderate depression (HADS-D ≥ 11, PHQ-9 ≥ 10) was 14% (95%CI 8 to 21%, I2 = 96%; Fig. 2b) [25, 26, 27, 28, 29, 30, 32]; excluding the single study using PHQ-9 did not improve heterogeneity (data not shown). Three studies reported the prevalence of depression using patient self-reported diagnosis: the pooled estimate was 22% (95%CI 9 to 39%, I2 = 98%) [40, 41, 42]. Only two studies reported depression prevalence using ICD-9 codes: the pooled estimate was 9% (95%CI 3 to 17%, I2 = 100%) [37, 38]. There was minor asymmetry in the funnel and Doi plots for mild depression, but major asymmetry for moderate depression (Supplementary Fig. 3).
Fig. 2

Forest plots showing the pooled prevalence of depression in studies of PsA. The top panel (a) shows prevalence estimates for at least mild depression, and bottom panel (b) at least moderate

Prevalence of anxiety and/or depression

Eight studies reported the combined prevalence of anxiety and/or depression. Figure 3a shows the pooled prevalence of anxiety or depression as 22% (95%CI 7 to 42%, I2 = 99%) [31, 34, 35, 39, 43, 44]. The prevalence using screening questionnaires was higher than studies using self-report or ICD code. Figure 3b shows the pooled prevalence of anxiety and depression as 29% (95%CI 20 to 38%, I2 = 94%) [26, 28, 30, 31]. There was no asymmetry in the funnel or Doi plots (Supplementary Fig. 4). Khraishi et al. reported a higher prevalence of these comorbidities in established than early PsA (17 vs 9.5%) [44].
Fig. 3

The top panel (a) shows prevalence estimates for anxiety or depression, and bottom panel (b) anxiety and depression in studies of PsA

Mental health comorbidities and disease activity

Only two studies compared disease activity scores in patients with and without comorbid mental health disorders. Freire et al. found that DAS28 (3.2 vs 2.9 p < 0.05) and pain visual analogue scale (VAS) (4.1 vs 3.0 p < 0.01) were higher in patients with anxiety than those without [30]. Similarly, DAS28 and pain VAS were higher in those with depression than those without. BASDAI was only assessed in a small subgroup, thus comparisons were underpowered. Michelsen et al. compared those with and without anxiety or depression [35]. In addition to DAS28 and pain VAS, they also found differences in the tender joint count, patient and evaluators global, but not swollen joint count, ESR or CRP (Table 2).
Table 2

Results from two studies comparing psoriatic arthritis patients with and without comorbid anxiety or depression

Study

Mental health disorder

Disease outcome measure

No mental health disorder

Mental health disorder present

P value

Freire (2011) [30]

Anxiety (HADS-A ≥ 11)

DAS28 (n = 341)

2.9 ± 1.3

3.2 ± 1.3

< 0.05

BASDAI (n = 41)

6.1 ± 1.1

9.2 ± 1.2

> 0.05

Pain VAS (n = 321)

3.0 ± 2.3

4.1 ± 2.3

< 0.01

Depression (HADS-D ≥ 11)

DAS28 (n = 341)

2.9 ± 1.3

3.3 ± 1.3

> 0.05

BASDAI (n = 41)

7.4 ± 1.2

7.1 ± 1.1

> 0.05

Pain VAS (n = 321)

3.1 ± 2.3

4.3 ± 2.2

< 0.01

Michelsen (2017) [35]

Anxiety or depression (EQ-5D) n = 728

DAS28-CRP

3.7 ± 1.1

4.0 ± 1.1

0.002

DAS28-ESR

3.8 ± 1.2

4.1 ± 1.3

0.002

Pain VAS

4.2 ± 2.3

5.3 ± 2.2

< 0.001

32 tender joint count

4 (2 to 8)

5 (2–10)

0.002

32 swollen joint count

3 (1–6)

2 (1–5)

0.16

Patient global assessment

4.5 ± 2.3

5.6 ± 2.2

0.001

Evaluators global assessment

3.1 ± 1.6

3.4 ± 1.6

0.001

CRP mg/L

6 (4–155)

7 (3–20)

0.70

ESR mm/h

15 (8–26)

17 (7–30)

0.42

SDAI

13.9 (9.6–21.0)

16.5 (11.4–23.3)

0.001

CDAI

12.8 (8.7–18.9)

14.8 (10.6–21.5)

0.001

Discussion

Mental health comorbidities are common among patients with PsA. In this systematic review and meta-analysis pooling data of over 30 thousand PsA patients, 1 in 3 screened positive for at least mild anxiety, while 1 in 5 reported at least mild depression. The prevalence of at least moderate anxiety (21%) and depression (14%) was lower on screening. Patients with anxiety and/or depression reported greater disease activity, although the number of studies was small. Sleep problems were also common (84%) but other mental health comorbidities were rarely reported.

High prevalence of mental health comorbidities among people with psoriasis is well recognised. Features of PsA can be considered additional psoriatic disease burden with accompanying functional impairment. Although meta-analysis estimates for PsA and psoriasis populations cannot be directly compared, several studies have demonstrated higher burden of anxiety and depression in psoriasis patients with PsA than those without: McDonough et al. showed that at least mild anxiety and depression were more prevalent in psoriasis patients with PsA than those without (17.7 vs 6.7%) [26]. Compared with the general population, the risk of depression in people with psoriasis was 14% higher, while those with PsA was 22% higher [49]. Among females, the risk of depression was 29% higher in those with psoriasis, but 52% higher if both psoriasis and PsA were present [50].

The prevalence of depression in this meta-analysis (14–20%) is similar to those reported in other inflammatory arthritides. A meta-analysis in rheumatoid arthritis (RA) reported at least moderate depression (HADS ≥ 11) in 15% of patients and at least mild depression (HADS ≥ 8) in 34% [40]. Virtually identical findings (15% moderate, 38% mild) were reported in an axial spondyloarthritis (axSpA) meta-analysis [51]. These similarities are somewhat unexpected since the proportions of females—who have a higher risk of depression—are very different in these three rheumatic diseases. Other characteristics important for the development of mental health disorders (e.g. age or comorbidity burden) are also likely to differ. In a large case-control study using UK primary care data, the authors adjusted for these confounders and found similar adjusted risk of depression across RA (HR 1.38), AS (HR 1.36), and mild psoriasis (HR 1.30), but higher in severe psoriasis (HR 1.71) [52]. The risk of anxiety appeared higher in AS (1.44) and psoriasis (1.28–1.33) than RA (1.10). No studies examined whether PsA severity was associated with prevalence or incidence of mental health disorders.

Patients with more severe disease may be at higher risk of developing mental health comorbidities, while some mental disorders have been shown to exacerbate the perception of pain [6]. Systemic inflammation may influence neurocognitive functions [53, 54]. Only two studies compared disease activity between PsA patients with and without mental health comorbidities. Both found significantly higher DAS28 and pain VAS in those with comorbid anxiety or depression, but there were no differences in swollen joint count, ESR or CRP. These cross-sectional studies do not allow us to distinguish the direction of any causal relationship, but the absence of differences in more objective measures of inflammation suggests it is more likely that these comorbidities are influencing reporting of disease severity. Healthcare professional should be mindful of these comorbidities when making treatment decisions based on composite disease scores; screening may be considered for these comorbidities to aid their diagnosis and management. Future studies should validate existing tools, such as the HADS, in patients with inflammatory rheumatic diseases.

One important finding of this review was the paucity of studies on suicide, self-harm, sexual health, substance misuse and other important mental health–related comorbidities. More research is needed in this area, particularly given that one study suggested a higher incidence rate of “any suicidality” in PsA than the general population [49]. Two studies in this review did highlight the importance of future studies of sleep on PsA outcome measures: 84% of patients screened positive for having poor-quality sleep. Michelsen et al. also reported that comorbid depression and anxiety were negative predictors of PsA remission [35].

A key strength of this review was a large number of studies and patients included. This allowed us to compare prevalence estimated from screening questionnaires against other methods, namely ICD codes. Prevalence of anxiety (6%) and depression (9%) were much lower using ICD codes, likely due to these codes’ low sensitivity for mental health diagnoses [55, 56]. Including a range of study designs can have implications for variations in effect estimates and may contribute to the high heterogeneity observed. However, heterogeneity remained when we stratified meta-analyses by criteria.

The main limitation was the fact that no studies used validated diagnostic criteria for mental health disorders, such as the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders. It is likely that screening criteria over-estimate while ICD codes under-estimate true prevalence. We also include studies that used different definitions of PsA, although it was not feasible to stratify by definitions of both PsA and mental health. This was taken into account during quality assessments. Almost all studies recruited patients from hospitals; these patients are likely to have more severe disease than a primary care sample. Finally, studies included in this review did not consider other comorbidities and PsA disease features. Fibromyalgia, metabolic syndrome and extra-articular manifestations are highly prevalent [7]; future studies should examine how these related conditions interact with mental health comorbidities and influence the management of PsA patients.

Conclusions

The results of this paper demonstrate that anxiety and depression are highly prevalent in psoriatic arthritis patients. Prevalence estimates are similar to those reported in RA, but some studies suggested a higher burden of anxiety and depression in psoriasis patients with PsA than those without. More research is needed on other mental health comorbidities, particularly sleep, suicide/self-harm and substance misuse. Comorbid anxiety or depression was associated with worse disease activity. Clinicians should be mindful of this when managing PsA patient. Patients with depression should be appropriately referred and managed. This is especially pertinent if depressive symptoms are thought to adversely influence assessments of treatment response.

Notes

Compliance with ethical standards

Disclosures

None

Supplementary material

10067_2019_4734_MOESM1_ESM.pdf (449 kb)
ESM 1 (PDF 448 kb)

References

  1. 1.
    Gladman D, Antoni C, Mease P, Clegg D, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17PubMedPubMedCentralGoogle Scholar
  2. 2.
    Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F (2017) The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44(3):279–285CrossRefPubMedGoogle Scholar
  3. 3.
    Ferreira BIRC, Abreu JLPDC, Reis JPGD, Figueiredo AMDC (2016) Psoriasis and associated psychiatric disorders. J Clin Aesthetic Dermatol 9(6):36–43Google Scholar
  4. 4.
    Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD (2017) The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheum 69(3):622–629CrossRefGoogle Scholar
  5. 5.
    Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin C-Y, Birt J et al (2019) The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis 21 annrheumdis-2018-215003Google Scholar
  6. 6.
    Bair MJ, Robinson RL, Katon W, Kroenke K (2003) Depression and pain comorbidity: a literature review. Arch Intern Med 163(20):2433–2445CrossRefPubMedGoogle Scholar
  7. 7.
    Lee YC, Lu B, Boire G, Haraoui BP, Hitchon CA, Pope JE et al (2013) Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 72(6):949–954CrossRefPubMedGoogle Scholar
  8. 8.
    Duffield SJ, Miller N, Zhao S, Goodson NJ.2018 Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology [Internet]. 16 [cited 2019 Feb 7]; Available from:  https://doi.org/10.1093/rheumatology/key112/4996713
  9. 9.
    Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefGoogle Scholar
  10. 10.
    Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53CrossRefPubMedGoogle Scholar
  11. 11.
    Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489–2498CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012CrossRefPubMedGoogle Scholar
  13. 13.
    Stern AF (2014) The hospital anxiety and depression scale. Occup Med (Lond) 64(5):393–394CrossRefGoogle Scholar
  14. 14.
    Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097CrossRefGoogle Scholar
  17. 17.
    National Collaborating Centre for Mental Health2009 Depression in adults with a chronic physical health problem: treatment and management. NICE Clinical Guidance 91 London: National Institute for Health and Clinical Excellence. [Internet]. Available from: https://www.nice.org.uk/guidance/CG91
  18. 18.
    Matcham F, Norton S, Steer S, Hotopf M (2016) Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet Disord 17:224CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63(2):162–169CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wells A, Shea B, O’Connell D, et al.2014 The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Internet]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  21. 21.
    Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T (2013) Meta-analysis of prevalence. J Epidemiol Community Health 67(11):974–978CrossRefPubMedGoogle Scholar
  22. 22.
    Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 63(12):1729–1735CrossRefGoogle Scholar
  23. 23.
    Husted JA, Tom BD, Farewell VT, Gladman DD (2012) Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Amp Res 64(5):758–765CrossRefGoogle Scholar
  24. 24.
    Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS (2011) Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 30(7):877–885CrossRefPubMedGoogle Scholar
  25. 25.
    Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP et al (2011) Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 38(5):898–903CrossRefPubMedGoogle Scholar
  26. 26.
    McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41(5):887–896CrossRefPubMedGoogle Scholar
  27. 27.
    Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS (2012) Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol JEADV 26(11):1436–1443CrossRefPubMedGoogle Scholar
  28. 28.
    Meesters JJL, Petersson IF, Bergman S, Haglund E, Jacobsson LTH, Bremander A (2014) Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clin Rheumatol 33(11):1649–1656CrossRefPubMedGoogle Scholar
  29. 29.
    Howells L, Chisholm A, Cotterill S, Chinoy H, Warren RB, Bundy C (2018) Impact of disease severity, illness beliefs, and coping strategies on outcomes in psoriatic arthritis. Arthritis Care Res 70(2):295–302CrossRefGoogle Scholar
  30. 30.
    Freire M, Rodríguez J, Möller I, Valcárcel A, Tornero C, Díaz G, Armendáriz Y, Paredes S (2011) Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7(1):20–26CrossRefPubMedGoogle Scholar
  31. 31.
    Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, Barker JNWN, Jackson K, Smith CH (2017) Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 176(4):1028–1034CrossRefPubMedGoogle Scholar
  32. 32.
    Kotsis K, Voulgari PV, Tsifetaki N, Machado MO, Carvalho AF, Creed F, Drosos AA, Hyphantis T (2012) Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res 64(10):1593–1601CrossRefGoogle Scholar
  33. 33.
    Papp K, Poulin Y, Vieira A, Shelton J, Poulin-Costello M (2014) Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. J Eur Acad Dermatol Venereol JEADV 28(5):581–589CrossRefPubMedGoogle Scholar
  34. 34.
    Torre-Alonso JC, Gratacós J, Rey-Rey JS, Valdazo de Diego JP, Urriticoechea-Arana A, Daudén E et al (2014) Development and validation of a new instrument to measure health-related quality of life in patients with psoriatic arthritis: the VITACORA-19. J Rheumatol 41(10):2008–2017CrossRefPubMedGoogle Scholar
  35. 35.
    Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, Wierød A, Kalstad S, Rødevand E, Krøll F, Haugeberg G, Kvien TK (2017) Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 76(11):1906–1910CrossRefPubMedGoogle Scholar
  36. 36.
    Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG et al (2014 Aug) Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol 41(8):1670–1674CrossRefPubMedGoogle Scholar
  37. 37.
    Davis JA, Robinson RL, Le TK, Xie J (2011) Incidence and impact of pain conditions and comorbid illnesses. J Pain Res 4:331–345CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kaine J, Song X, Kim G, Hur P, Palmer JB (2019) Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm 25(1):122–132PubMedGoogle Scholar
  39. 39.
    Ballegaard C, Højgaard P, Dreyer L, Cordtz R, Jørgensen TS, Skougaard M, Tarp S, Kristensen LE (2018) Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res 70(4):592–599CrossRefGoogle Scholar
  40. 40.
    Altobelli E, Maccarone M, Petrocelli R, Marziliano C, Giannetti A, Peris K, Chimenti S (2007) Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 7:59CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L (2018) Comorbidity in psoriatic arthritis and rheumatoid arthritis: comorbidity in inflammatory arthritis. Intern Med J 48(11):1360–1368CrossRefPubMedGoogle Scholar
  42. 42.
    Patel P, Rosen CF, Chandran V, Ye YJ, Gladman DD (2018) Addressing comorbidities in psoriatic disease. Rheumatol Int 38(2):219–227CrossRefPubMedGoogle Scholar
  43. 43.
    Husted JA, Thavaneswaran A, Chandran V, Gladman DD (2013) Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 40(8):1349–1356CrossRefPubMedGoogle Scholar
  44. 44.
    Khraishi M, Aslanov R, Rampakakis E, Pollock C, Sampalis JS (2014) Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol 33(10):1495–1500CrossRefPubMedGoogle Scholar
  45. 45.
    Löfvendahl S, Jöud A, Petersson IF, Theander E, Svensson Å, Carlsson KS (2018 Apr) Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. Eur J Health Econ 19(3):447–462CrossRefPubMedGoogle Scholar
  46. 46.
    Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ et al (2016) Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Med U S 95(22)Google Scholar
  47. 47.
    Wong ITY, Chandran V, Li S, Gladman DD (2017) Sleep disturbance in psoriatic disease: prevalence and associated factors. J Rheumatol 44(9):1369–1374CrossRefPubMedGoogle Scholar
  48. 48.
    Gezer O, Batmaz İ, Sariyildiz MA, Sula B, Ucmak D, Bozkurt M, Nas K (2017) Sleep quality in patients with psoriatic arthritis. Int J Rheum Dis 20(9):1212–1218CrossRefPubMedGoogle Scholar
  49. 49.
    Wu JJ, Penfold RB, Primatesta P, Fox TK, Stewart C, Reddy SP, Egeberg A, Liu J, Simon G (2017) The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol 31(7):1168–1175CrossRefPubMedGoogle Scholar
  50. 50.
    Dommasch ED, Li T, Okereke OI, Li Y, Qureshi AA, Cho E (2015) Risk of depression in women with psoriasis: a cohort study. Br J Dermatol 173(4):975–980CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Zhao S, Thong D, Miller N, Duffield SJ, Hughes DM, Chadwick L et al (2018) The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther 20(1)Google Scholar
  52. 52.
    Dregan A, Matcham F, Harber-Aschan L, Rayner L, Brailean A, Davis K, Hatch S, Pariante C, Armstrong D, Stewart R, Hotopf M (2019 May 1) Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation. Ann Rheum Dis 78(5):688–695CrossRefPubMedGoogle Scholar
  53. 53.
    Chimenti MS, Caso F, Alivernini S, De Martino E, Costa L, Tolusso B et al (2019 Jun) Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease. Autoimmun Rev 18(6):565–575CrossRefGoogle Scholar
  54. 54.
    Zunszain PA, Hepgul N, Pariante CM (2013) Inflammation and depression. Curr Top Behav Neurosci 14:135–151CrossRefPubMedGoogle Scholar
  55. 55.
    Fiest KM, Jette N, Quan H, St. Germaine-Smith C, Metcalfe A, Patten SB, et al. Systematic review and assessment of validated case definitions for depression in administrative data. BMC Psychiatry [Internet]. 2014 Oct 17 [cited 2019 Apr 17];14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201696/
  56. 56.
    Kim HM, Smith EG, Stano CM, Ganoczy D, Zivin K, Walters H, Valenstein M (2012 Jan 23) Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res 12:18CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Sizheng Steven Zhao
    • 1
    • 2
  • Natasha Miller
    • 1
    • 3
  • Nicholas Harrison
    • 2
  • Stephen J. Duffield
    • 1
  • Mrinalini Dey
    • 1
    • 2
  • Nicola J. Goodson
    • 1
    • 2
    Email author
  1. 1.Musculoskeletal Biology I, Institute of Ageing and Chronic DiseaseUniversity of LiverpoolLiverpoolUK
  2. 2.Department of Academic RheumatologyAintree University HospitalLiverpoolUK
  3. 3.School of MedicineUniversity of LiverpoolLiverpoolUK

Personalised recommendations